Looking for a way to improve the limit of detection for low-frequency CNVs and mutations?
Explore NuProbe’s technologies for oncology translational research and development at the 12th World Clinical Biomarkers & CDx Summit – proprietary technologies to enable ultrasensitive detection while overcoming the challenges of current methods.
BIOMARKER DISCOVERY & TRANSLATIONAL DEVELOPMENT SESSION
Emerging Solutions for Non-Invasive Cancer Monitoring
THURSDAY, SEPTEMBER 29, 2022 | 12:35 PM
This talk will discuss the current state, advantages, and limitations of non-invasive liquid biopsies in oncology. We will also introduce Blocker Displacement Amplification and Quantitative Amplicon Sequencing technologies and discuss how these technologies can improve liquid biopsies while highlighting applications of these technologies in non-invasive longitudinal monitoring.
Connect With Us
Nick Gallerani, Ph.D.
SENIOR BUSINESS DEVELOPMENT ASSOCIATE
Nicholas Gallerani, Ph.D., serves as a Senior Business Development Associate at NuProbe. Prior to joining NuProbe, he received his Ph.D. in Pathobiology and Molecular Medicine from Columbia University and was a Fellow at Columbia Technology Ventures, where he assessed new technologies generated by their research labs.